Salmeterol and matching placebo were bought from third-party vendors.2 percent, 92.3 percent, and 93.2 percent, respectively. The informed-consent document was amended in April 2008 to acknowledge the FDA’s MedWatch alert concerning the association between tiotropium and the chance of stroke. No individual withdrew because of this modification. Statistical Analysis The principal hypothesis was that the addition of tiotropium to an inhaled glucocorticoid would be more advanced than a doubling of the dosage of the inhaled glucocorticoid with respect to the morning hours PEF. The secondary hypothesis was that the addition of tiotropium to an inhaled glucocorticoid wouldn’t normally be inferior compared to the addition of salmeterol with respect to the morning PEF, the prebronchodilator FEV1, and the proportion of asthma-control times.Several hundred other companies have already been affected similarly. Our medical trials and other important business actions are proceeding well and so are unaffected by this modification. Yours Sincerely, Thomas A. Moore Chairman/CEO.. Advaxis CEO issues statement to shareholders regarding recent common stock transition Thomas A. Moore, cEO and chairman of Advaxis, Inc., , the live, attenuated Listeria monocytogenes vaccine firm, has issued the next statement to shareholders regarding the recent changeover to the OTCQB from the OTCBB: Dear Fellow Shareholders, Related StoriesNew vaccine applicant shows great promise at fighting respiratory syncytial virusResearchers reveal why malaria vaccine provides just moderate protection among vaccinated childrenResearch provides leads for new strategies to develop HIV vaccineOver the last few days, achieving the Company’s stock quote information has been incredibly difficult.